PRGN-3008 / Precigen - LARVOL DELTA

Increased Potency, Persistence, and Stem Cell Memory/Naïve Phenotype is Achieved with PRGN-3008 UltraCAR-T, an Overnight-Manufactured CD19 CAR-T Cell Expressing membrane-bound IL-15 and miRNA-based PD-1 Blockade from a Single Non-Viral Transposon (ASGCT 2025) - "These results demonstrate that the PRGN-3008 has potential to be the best-in-class treatment. Disease Focus of Abstract:Cancer Hematologic"

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Oncology • CD19 • IL15

Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PRNewswire) - "Preclinical data for PRGN-3008 were presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in a poster presentation....Preclinical data showed that in in vivo tumor models, a single administration of PRGN-3008 enhanced expansion and persistence, produced robust antitumor efficacy with complete tumor clearance, and demonstrated significantly longer survival compared to conventional CD19 CAR-T cells. In a simulation of tumor relapse in the in vivo model, PRGN-3008 demonstrated persistence and long-term antitumor immunity extending overall survival without additional PRGN-3008 treatment."

Preclinical • Oncology